ESTRO Multidisciplinary Management of Breast Cancer 2017

Tailoring risk factors

• Subtype, margin involvement extent (focal or gross), planned adjuvant therapy.

• Probably not yet

• Most studies have excluded grossly positive margins and recruitment to trials would be challenging

• Are we at the stage where we can tailor our decisions?